Malaria Vaccines for the World

8-10 May 2019, University of Oxford, Oxford, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Provisional Conference Programme | Wednesday 8th May 2019

SESSION 1:
OPENING PLENARY SESSION

Moderator: Simon Draper (University of Oxford, Oxford, UK)

‘Title to be confirmed’
Speaker to be confirmed

‘Title to be confirmed’
Speaker to be confirmed

Coffee Break & Posters Set-Up

SESSION 2:
PfSPZ-Based Vaccines: Phase 3 to Licensure to Deployment to Use in Elimination Campaigns to Next Generations

Moderators: Alassane Dicko (Bamako Malaria Research and Training Center) and Peter Kremsner (University of Tübingen)

‘Finalizing an immunization regimen for PfSPZ Vaccine for Phase 3 clinical trials in non-immunes’
Benjamin Mordmüller (University of Tübingen, Tubingen, Germany)

‘Finalizing an immunization regimen for PfSPZ Vaccine for Phase 3 clinical trials in semi-immune adults in Africa’
Said Jongo (Ifakara Health Institute and Bioko Island Malaria Elimination Program)

‘Current status of and medium-term plans for PfSPZ Vaccine’
Thomas L. Richie (Sanaria Inc., Maryland, USA)

‘Plans for use of PfSPZ Vaccine for Geographically Focused Elimination Campaigns’
Salim Abdulla (Ifakara Health Institute and Bioko Island Malaria Elimination Program)

‘Developing a PfSPZ-CVac regimen that provides high level protection against heterologous CHMI’
Agnes Mwakingwe (Laboratory of Malaria Immunology and Vaccinology, NIAID, NIH, Bethesda, Maryland, USA)

‘Current status of early arresting genetically altered PfSPZ vaccines, PfSPZ-GA1’
Meta Roestenberg (Leiden University Medical Center, Leiden, The Netherlands)

‘Current status of early arresting genetically altered PfSPZ vaccines, PfSPZ-GAP3KO’
Stefan Kappe (Seattle Children’s Hospital Research Foundation, Seattle, Washington, USA)

Discussion

Lunch Break & Posters

SESSION 3:
PfSPZ-Based Vaccines: Innovations and immunology to improve efficacy and reduce cost of goods

Moderators: Patrick Duffy (LMIV, NIAID, NIH) and Peter F. Billingsley (Sanaria Inc., Maryland, USA)

‘Production of fully infectious, immunogenic PfSPZ in vitro
Abraham Eappen (Sanaria Inc., Maryland, USA)

‘Hybrid strains and mixed strains of PfSPZ for increasing genetic diversity’
B. Kim Lee Sim (Sanaria Inc., Maryland, USA)

‘Development of late liver stage arresting genetically attenuated PfSPZ and parasites expressing heterologous antigens’
Shahid Khan and Chris Janse (Leiden University Medical Center, Leiden, The Netherlands)

‘Development of late liver stage arresting genetically attenuated PfSPZ and parasites expressing heterologous antigens’
Ashley Vaughn (Seattle Children’s Hospital Research Foundation, Seattle, Washington, USA)

‘Improving immunogenicity with adjuvants’
Sumana Chakravarty (Sanaria Inc., Maryland, USA)

‘What have we learned and not learned from immunological studies during vaccine efficacy studies?’
Claudia Daubenberger (Swiss TPH , Switzerland)

‘Complementing protection with human monoclonal antibodies’
Stephen L. Hoffman (Sanaria Inc., Maryland, USA)

Discussion

Tea Break & Posters

SESSION 4:
Recent Advances – Blood-Stage and Transmission-Blocking Vaccines

Moderator: To be confirmed

‘Safety, immunogenicity and efficacy of the Plasmodium falciparum blood-stage vaccine RH5.1/ASO18’
Sarah Silk (University of Oxford, Oxford, UK)

‘Safety, tolerability and immunogenicity of ChAd63 and MVA expressing P. falciparum RH5 in African adults, young children and infants’
Ally Olotu1,2, Saumu Ahmed1, Maximillian Mpina1, Wilmina Kalinga1, Florence Milando1, Mohamed Rashid1, Said Jongo1, Yrene Themistocleous3, Jordan R. Barrett3, Alison M. Lawrie3, Fay L. Nugent3, Sarah E. Silk3, Angela M. Minassian3 and Simon J. Draper3 (1 Health Institute; 2 KEMRI-Wellcome Trust Research Programme; 3 The Jenner Institute, University of Oxford, Oxford, UK)

‘Status of PfEMP1 vaccine development’
Louise Turner, Morten Nielsen, Ali Salanti, Thor G. Theander and Thomas Lavstsen (University of Copenhagen, Copenhagen, Denmark)

‘Pfs48/45 as a malaria transmission-blocking vaccine’
David Mekhaiel (University of Oxford, Oxford, UK)

‘HBsAg-based VLP vaccine platforms for transmission-blocking malaria vaccines’
Arianna Marini (University of Oxford, Oxford, UK)

‘Modelling and simulations to investigate alternative use of vaccines for malaria control, elimination and prevention of resurgence’
Flavia Camponovo1,2 and Melissa A. Penny1,2 (1 Swiss Tropical and Public Health Institute, Basel, Switzerland; 2 University of Basel, Basel, Switzerland)

 

MVW 2019 Delegates

Login details will be supplied after you have registered for the event.


MVW 2019 Sponsors

  • Malaria World
  • Inovio Pharmaceuticals
  • VisMederi
  • MVI PATH
  • MW Journal
  • Aldevron
  • EVI
  • Sanaria
  • NatureGeneTherapy.com
  • Mymetics
  • DNAvaccine.com
  • Malaria No More

MVW 2019 Downloads

MVW 2019 Leaflet

MVW 2019 Mailing List

Name
E-mail Address
What is 3+2-1?